Free Contraception May Turn-Out Votes in November but Few Women Have Turned to the News to Learn What’s Covered
Phoenix Marketing 360° Birth Control Market Tracking program finds only 36% of women who currently use or plan to use prescription birth control are even following the news about the Affordable Care Act
Durham, NC (PRWEB) October 10, 2012
Effective August 1 of this year, 47 million women became eligible for free preventive services under the Affordable Care Act (ACA) and can begin participating in their health plans’ next enrollment period. All FDA-approved birth control methods including hormonal pills, patches, IUDs and IUSs are covered. For most women who have a co-payment for their contraception this could result in an average savings of $200 a year. However, according to the Phoenix Marketing 360° Birth Control Market Tracking program, only 36% of women who currently use or plan to use prescription birth control are even following the news about the Affordable Care Act. This represents a significant shortfall in educating woman about the program as well as a huge opportunity for the providers of prescription birth control products who can best target this audience.
Phoenix Healthcare, a division of Phoenix Marketing International, interviews 1,000 women in the birth control market every month to learn what they are using, when and if they are planning to switch brands or methods, along with tracking their use of branded DTC ads to guide what birth control methods and products they talk to their doctor about.
The Phoenix Healthcare birth control audit is part of a growing family of disease category consumer studies that offer Phoenix exclusive 360° Marketview©. Phoenix Healthcare 360° Marketview studies currently cover 40% of all DTC spending in the US with research in the following categories: Contraceptives, Dyslipidemia, Schizophrenia, Rheumatoid Arthritis, Plaque Psoriasis, Crohn’s Disease, Psoriatic Arthritis, Ankylosing Spondylitis, and Men’s Health. A partial list of the major brands tracked in these programs include: Abilify, Actemra, AndroGel, Cialis, Cimzia, Ella, Enbrel, Essure, Generess FE, Humira, Invega Sustenna, Januvia, Levitra, Lo Loestrin FE, Mirena, Niaspan, Orencia, Ortho Evra and Ortho TriCyclen-Lo, ParaGard, Plan B, Rapiflo, Remicade, Rituxan, Seroquel XR, Simponi, Stelara, Uloric, Viagra, Victoza, and Zyprexa Relprevv.
For more information about the kind of brand tracking information is available in the 360° Contraceptive Marketview© study contact John Duggan at 508-315-6184.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/10/prweb9974804.htm